9,592 Globus Medical, Inc. $GMED Shares Bought by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. boosted its position in Globus Medical, Inc. (NYSE:GMED) by 21.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 54,598 shares of the medical device company’s stock after purchasing an additional 9,592 shares during the period. Washington Trust Advisors Inc.’s holdings in Globus Medical were worth $4,089,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Inspire Investing LLC increased its holdings in Globus Medical by 464.8% during the third quarter. Inspire Investing LLC now owns 41,600 shares of the medical device company’s stock valued at $3,116,000 after buying an additional 34,234 shares during the last quarter. BIP Wealth LLC raised its position in Globus Medical by 28.0% in the third quarter. BIP Wealth LLC now owns 5,202 shares of the medical device company’s stock worth $390,000 after acquiring an additional 1,137 shares during the period. Sepio Capital LP purchased a new position in shares of Globus Medical during the 3rd quarter worth $302,000. Root Financial Partners LLC purchased a new position in shares of Globus Medical during the 3rd quarter worth $29,000. Finally, Axxcess Wealth Management LLC purchased a new position in shares of Globus Medical during the 3rd quarter worth $261,000. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Stock Performance

Shares of Globus Medical stock traded down $0.18 during trading hours on Friday, hitting $81.47. The company’s stock had a trading volume of 768,420 shares, compared to its average volume of 1,483,170. The business has a 50 day moving average price of $78.03 and a two-hundred day moving average price of $81.19. Globus Medical, Inc. has a 12-month low of $59.51 and a 12-month high of $101.40. The company has a market cap of $10.94 billion, a PE ratio of 20.84, a PEG ratio of 1.32 and a beta of 0.96.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. The firm had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, research analysts anticipate that Globus Medical, Inc. will post 4.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on GMED shares. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. Stifel Nicolaus lowered their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research report on Wednesday, July 8th. Royal Bank Of Canada cut their price target on Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday, September 18th. Finally, Wells Fargo & Company reduced their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.46.

Insider Activity at Globus Medical

In other news, Director Stephen T. Zarrilli sold 25,000 shares of Globus Medical stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James Tobin sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares in the company, valued at $1,118,700. This trade represents a 66.67% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.